Your browser doesn't support javascript.
loading
Glycodeoxycholic acid as alternative treatment in 3ß-hydroxy-Δ5-C27-steroid-oxidoreductase: a case report.
Majait, S; Vaz, F M; Kemper, E Marleen; Bootsma, A H; Groen, A K; Nieuwdorp, M; Soeters, Maarten R.
Afiliação
  • Majait S; Department of Pharmacy and Clinical Pharmacology, Amsterdam UMC Location University of Amsterdam, Amsterdam, Netherlands.
  • Vaz FM; Department of Clinical Chemistry and Pediatrics, Laboratory Genetic Metabolic Diseases, Emma Children's Hospital, Amsterdam UMC Location University of Amsterdam, Amsterdam, Netherlands.
  • Kemper EM; Inborn Errors of Metabolism, Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, Netherlands.
  • Bootsma AH; Core Facility Metabolomics, Amsterdam UMC Location University of Amsterdam, Amsterdam, Netherlands.
  • Groen AK; Department of Experimental Vascular Medicine, Amsterdam University Medical Center, Amsterdam, Netherlands.
  • Nieuwdorp M; Department of Clinical Chemistry and Pediatrics, Laboratory Genetic Metabolic Diseases, Emma Children's Hospital, Amsterdam UMC Location University of Amsterdam, Amsterdam, Netherlands.
  • Soeters MR; Department of Experimental Vascular Medicine, Amsterdam University Medical Center, Amsterdam, Netherlands.
Front Pediatr ; 12: 1418963, 2024.
Article em En | MEDLINE | ID: mdl-39005507
ABSTRACT

Background:

3ß-hydroxy-Δ5-C27-steroid-oxidoreductase (3ß-HSD) deficiency is a bile acid synthesis disorder that leads to the absence of normal primary bile acids and the accumulation of abnormal bile acids. This results in cholestatic jaundice, fat-soluble vitamin deficiency, acholic or fatty stools and failure to thrive. Bile acid supplementation is used to treat 3ß-HSD-deficiency and its symptoms.

Methods:

This report details the case of a 28-year-old woman diagnosed with 3ß-HSD-deficiency, who was treated with glycine-conjugated deoxycholic acid (gDCA).

Results:

gDCA treatment successfully restored normal bile acid levels, improved body weight by reducing fat malabsorption, and was well-tolerated with no observed liver problems or side effects.

Conclusions:

As a potent FXR ligand, gDCA might exert its action through FXR activation leading to bile acid synthesis regulation.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article